Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Cystadenocarcinoma, Serous | 41 | 2022 | 486 | 6.940 |
Why?
|
Ovarian Neoplasms | 94 | 2023 | 4638 | 6.100 |
Why?
|
Endometrial Neoplasms | 47 | 2023 | 1341 | 5.500 |
Why?
|
Peritoneal Neoplasms | 24 | 2022 | 821 | 4.980 |
Why?
|
Carcinoma, Endometrioid | 23 | 2023 | 323 | 4.270 |
Why?
|
Fallopian Tube Neoplasms | 9 | 2022 | 153 | 3.220 |
Why?
|
Uterine Neoplasms | 25 | 2022 | 545 | 2.990 |
Why?
|
Uterine Cervical Neoplasms | 53 | 2023 | 1833 | 2.500 |
Why?
|
Vulvar Neoplasms | 16 | 2021 | 236 | 1.990 |
Why?
|
Uterine Cervical Dysplasia | 32 | 2012 | 219 | 1.770 |
Why?
|
Immunohistochemistry | 60 | 2022 | 7548 | 1.710 |
Why?
|
Mesothelioma | 5 | 2022 | 544 | 1.650 |
Why?
|
Carcinoma | 14 | 2023 | 2578 | 1.570 |
Why?
|
Neoplasms, Multiple Primary | 15 | 2014 | 551 | 1.370 |
Why?
|
Biomarkers, Tumor | 53 | 2022 | 10331 | 1.290 |
Why?
|
Leiomyosarcoma | 6 | 2020 | 223 | 1.240 |
Why?
|
Female | 247 | 2023 | 141928 | 1.230 |
Why?
|
Cervix Uteri | 19 | 2012 | 253 | 1.040 |
Why?
|
Carcinosarcoma | 5 | 2019 | 146 | 1.020 |
Why?
|
Adenocarcinoma | 20 | 2023 | 7789 | 0.990 |
Why?
|
Papillomaviridae | 9 | 2021 | 624 | 0.970 |
Why?
|
Endometriosis | 3 | 2023 | 214 | 0.960 |
Why?
|
Neoplasms, Cystic, Mucinous, and Serous | 6 | 2017 | 108 | 0.930 |
Why?
|
Mesonephroma | 1 | 2023 | 17 | 0.920 |
Why?
|
Adult | 125 | 2023 | 77950 | 0.910 |
Why?
|
Sarcoma, Endometrial Stromal | 6 | 2015 | 14 | 0.890 |
Why?
|
Middle Aged | 115 | 2023 | 86204 | 0.880 |
Why?
|
Humans | 252 | 2023 | 261506 | 0.860 |
Why?
|
Asbestos | 1 | 2022 | 35 | 0.860 |
Why?
|
Neoplasm Grading | 19 | 2022 | 1742 | 0.850 |
Why?
|
Cysts | 2 | 2022 | 197 | 0.830 |
Why?
|
Endometrial Hyperplasia | 4 | 2020 | 112 | 0.830 |
Why?
|
Neoplasm Recurrence, Local | 31 | 2022 | 10035 | 0.810 |
Why?
|
Lymphatic Metastasis | 15 | 2021 | 4844 | 0.810 |
Why?
|
Sentinel Lymph Node | 4 | 2021 | 216 | 0.800 |
Why?
|
Carcinoma, Neuroendocrine | 5 | 2021 | 716 | 0.790 |
Why?
|
Wolffian Ducts | 2 | 2020 | 24 | 0.790 |
Why?
|
Aged | 89 | 2023 | 70117 | 0.790 |
Why?
|
Adenocarcinoma in Situ | 1 | 2021 | 31 | 0.780 |
Why?
|
Neoplasm Staging | 48 | 2022 | 13658 | 0.780 |
Why?
|
Teratoma | 4 | 2015 | 236 | 0.740 |
Why?
|
Hysterectomy | 12 | 2021 | 611 | 0.710 |
Why?
|
PAX8 Transcription Factor | 2 | 2016 | 55 | 0.710 |
Why?
|
Papillomavirus Infections | 9 | 2021 | 980 | 0.700 |
Why?
|
Ovary | 10 | 2020 | 668 | 0.690 |
Why?
|
Diagnosis, Differential | 27 | 2022 | 4744 | 0.670 |
Why?
|
Adenocarcinoma, Clear Cell | 5 | 2011 | 178 | 0.660 |
Why?
|
Adenocarcinoma, Mucinous | 4 | 2020 | 436 | 0.640 |
Why?
|
Aged, 80 and over | 43 | 2021 | 29902 | 0.620 |
Why?
|
Cystadenoma, Serous | 4 | 2013 | 29 | 0.610 |
Why?
|
Practice Guidelines as Topic | 9 | 2021 | 2403 | 0.610 |
Why?
|
Endometrium | 5 | 2020 | 470 | 0.590 |
Why?
|
Cystadenoma, Mucinous | 2 | 2009 | 34 | 0.580 |
Why?
|
Vulva | 3 | 2015 | 37 | 0.560 |
Why?
|
Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2020 | 469 | 0.550 |
Why?
|
Exocrine Glands | 1 | 2015 | 15 | 0.540 |
Why?
|
Gynecology | 9 | 2021 | 217 | 0.540 |
Why?
|
Lymph Nodes | 8 | 2019 | 2967 | 0.540 |
Why?
|
Pathologists | 9 | 2022 | 91 | 0.520 |
Why?
|
Biopsy | 17 | 2022 | 3443 | 0.510 |
Why?
|
Carcinoma, Squamous Cell | 12 | 2020 | 5437 | 0.510 |
Why?
|
Gynecologic Surgical Procedures | 9 | 2016 | 356 | 0.480 |
Why?
|
Immunoenzyme Techniques | 11 | 2009 | 1165 | 0.480 |
Why?
|
Vaginal Neoplasms | 6 | 2014 | 152 | 0.470 |
Why?
|
Colorectal Neoplasms | 3 | 2020 | 3578 | 0.440 |
Why?
|
Cell Nucleus | 12 | 2013 | 1620 | 0.440 |
Why?
|
Endodermal Sinus Tumor | 3 | 2017 | 47 | 0.440 |
Why?
|
Smooth Muscle Tumor | 2 | 2009 | 9 | 0.440 |
Why?
|
Disease-Free Survival | 20 | 2023 | 10001 | 0.440 |
Why?
|
Lymph Node Excision | 9 | 2021 | 1959 | 0.440 |
Why?
|
Cystadenocarcinoma, Papillary | 6 | 2022 | 82 | 0.430 |
Why?
|
Lymphangioma | 2 | 2003 | 36 | 0.430 |
Why?
|
Chemotherapy, Adjuvant | 9 | 2021 | 3890 | 0.430 |
Why?
|
Young Adult | 26 | 2022 | 21445 | 0.430 |
Why?
|
Mitotic Index | 7 | 2016 | 162 | 0.430 |
Why?
|
Prognosis | 36 | 2019 | 21713 | 0.420 |
Why?
|
Tumor Suppressor Protein p53 | 5 | 2021 | 3552 | 0.410 |
Why?
|
Cell Transformation, Neoplastic | 5 | 2017 | 2359 | 0.400 |
Why?
|
Dermatofibrosarcoma | 2 | 2010 | 72 | 0.400 |
Why?
|
Uterine Cervical Diseases | 5 | 2006 | 25 | 0.390 |
Why?
|
Carcinoma in Situ | 9 | 2015 | 487 | 0.390 |
Why?
|
Neoadjuvant Therapy | 4 | 2021 | 4975 | 0.390 |
Why?
|
Retroperitoneal Neoplasms | 2 | 2012 | 262 | 0.380 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 1 | 2015 | 674 | 0.380 |
Why?
|
Nevus, Blue | 1 | 2010 | 40 | 0.380 |
Why?
|
Societies, Medical | 10 | 2021 | 1335 | 0.370 |
Why?
|
Cystadenocarcinoma, Mucinous | 1 | 2009 | 21 | 0.350 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 15 | 2021 | 15862 | 0.340 |
Why?
|
Neoplasm Invasiveness | 10 | 2020 | 3981 | 0.340 |
Why?
|
Precancerous Conditions | 10 | 2012 | 1058 | 0.340 |
Why?
|
Peritoneum | 3 | 2022 | 150 | 0.330 |
Why?
|
Colposcopy | 9 | 2011 | 78 | 0.330 |
Why?
|
Diagnostic Errors | 2 | 2011 | 509 | 0.330 |
Why?
|
Submandibular Gland Neoplasms | 1 | 2008 | 37 | 0.320 |
Why?
|
Retrospective Studies | 37 | 2022 | 37905 | 0.320 |
Why?
|
Stomach Neoplasms | 1 | 2021 | 2278 | 0.320 |
Why?
|
Neuroectodermal Tumors, Primitive, Peripheral | 1 | 2008 | 36 | 0.310 |
Why?
|
Predictive Value of Tests | 11 | 2022 | 4892 | 0.310 |
Why?
|
Skin Neoplasms | 4 | 2010 | 4654 | 0.310 |
Why?
|
Ki-67 Antigen | 6 | 2013 | 666 | 0.300 |
Why?
|
Neoplasm Proteins | 9 | 2013 | 3230 | 0.300 |
Why?
|
Granulosa Cell Tumor | 3 | 2022 | 77 | 0.300 |
Why?
|
Neoplasm Regression, Spontaneous | 3 | 2011 | 34 | 0.300 |
Why?
|
Combined Modality Therapy | 17 | 2013 | 8865 | 0.290 |
Why?
|
Fallopian Tubes | 3 | 2022 | 119 | 0.290 |
Why?
|
Germ-Line Mutation | 2 | 2022 | 1046 | 0.290 |
Why?
|
Hemangiosarcoma | 1 | 2009 | 234 | 0.290 |
Why?
|
Myofibroblasts | 2 | 2022 | 133 | 0.290 |
Why?
|
Treatment Outcome | 17 | 2022 | 32848 | 0.280 |
Why?
|
CA-125 Antigen | 2 | 2007 | 226 | 0.280 |
Why?
|
Microsatellite Instability | 3 | 2016 | 400 | 0.280 |
Why?
|
Time Factors | 10 | 2020 | 12926 | 0.270 |
Why?
|
Spectrometry, Fluorescence | 9 | 2011 | 209 | 0.270 |
Why?
|
S100 Calcium Binding Protein G | 6 | 2012 | 50 | 0.270 |
Why?
|
Carcinoid Tumor | 1 | 2007 | 280 | 0.260 |
Why?
|
Microscopy, Confocal | 6 | 2007 | 663 | 0.260 |
Why?
|
Laparoscopy | 4 | 2020 | 1225 | 0.250 |
Why?
|
Adolescent | 22 | 2022 | 31252 | 0.240 |
Why?
|
Statistics as Topic | 1 | 2005 | 445 | 0.240 |
Why?
|
Lymphatic Diseases | 1 | 2004 | 128 | 0.240 |
Why?
|
Carcinoma, Small Cell | 3 | 2021 | 408 | 0.230 |
Why?
|
Endometrial Stromal Tumors | 2 | 2013 | 7 | 0.230 |
Why?
|
Sex Cord-Gonadal Stromal Tumors | 4 | 2004 | 35 | 0.230 |
Why?
|
Mutation | 9 | 2022 | 15179 | 0.230 |
Why?
|
Cohort Studies | 5 | 2022 | 9244 | 0.230 |
Why?
|
Dynamin III | 1 | 2022 | 3 | 0.230 |
Why?
|
Melanoma | 6 | 2016 | 5317 | 0.230 |
Why?
|
Calbindin 2 | 6 | 2012 | 40 | 0.230 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 3 | 2020 | 1331 | 0.220 |
Why?
|
Disease Progression | 8 | 2020 | 6682 | 0.220 |
Why?
|
Telomerase | 2 | 2022 | 525 | 0.210 |
Why?
|
Neoplasms, Connective Tissue | 1 | 2022 | 20 | 0.210 |
Why?
|
MutS Homolog 2 Protein | 1 | 2022 | 178 | 0.210 |
Why?
|
Image Interpretation, Computer-Assisted | 4 | 2008 | 592 | 0.210 |
Why?
|
Polyploidy | 1 | 2022 | 73 | 0.210 |
Why?
|
Epithelioid Cells | 1 | 2022 | 43 | 0.200 |
Why?
|
Hormones | 1 | 2003 | 266 | 0.200 |
Why?
|
Ovariectomy | 4 | 2016 | 330 | 0.200 |
Why?
|
Pathology, Clinical | 1 | 2022 | 152 | 0.200 |
Why?
|
Survival Analysis | 7 | 2020 | 9180 | 0.200 |
Why?
|
Carcinoma, Large Cell | 1 | 2021 | 94 | 0.190 |
Why?
|
Pregnancy Complications, Neoplastic | 1 | 2002 | 222 | 0.190 |
Why?
|
Keratins | 5 | 2013 | 330 | 0.190 |
Why?
|
Tomography, Optical Coherence | 1 | 2005 | 501 | 0.190 |
Why?
|
Prophylactic Surgical Procedures | 1 | 2020 | 23 | 0.190 |
Why?
|
Genital Neoplasms, Female | 3 | 2020 | 735 | 0.190 |
Why?
|
Salpingo-oophorectomy | 1 | 2020 | 50 | 0.190 |
Why?
|
Paget Disease, Extramammary | 2 | 2015 | 55 | 0.190 |
Why?
|
Fatal Outcome | 3 | 2009 | 829 | 0.190 |
Why?
|
Image Cytometry | 4 | 2004 | 47 | 0.180 |
Why?
|
Cytoreduction Surgical Procedures | 2 | 2022 | 475 | 0.180 |
Why?
|
Homozygote | 1 | 2022 | 717 | 0.180 |
Why?
|
Follow-Up Studies | 14 | 2020 | 14889 | 0.180 |
Why?
|
Antineoplastic Agents | 13 | 2021 | 14289 | 0.180 |
Why?
|
Melanoma-Specific Antigens | 3 | 2004 | 82 | 0.180 |
Why?
|
Fenretinide | 3 | 2005 | 96 | 0.180 |
Why?
|
Calcinosis | 1 | 2003 | 423 | 0.170 |
Why?
|
Inhibins | 4 | 2004 | 128 | 0.170 |
Why?
|
Salpingectomy | 2 | 2016 | 43 | 0.170 |
Why?
|
Integrases | 1 | 2020 | 262 | 0.170 |
Why?
|
Sequence Deletion | 1 | 2022 | 875 | 0.170 |
Why?
|
Pathology, Molecular | 2 | 2019 | 128 | 0.170 |
Why?
|
Myometrium | 2 | 2013 | 79 | 0.170 |
Why?
|
Premenopause | 3 | 2020 | 131 | 0.170 |
Why?
|
Epithelium | 5 | 2011 | 720 | 0.160 |
Why?
|
Diagnosis, Computer-Assisted | 3 | 2012 | 164 | 0.160 |
Why?
|
Postmenopause | 3 | 2005 | 378 | 0.160 |
Why?
|
Proto-Oncogene Proteins B-raf | 3 | 2016 | 1283 | 0.160 |
Why?
|
Survival Rate | 13 | 2017 | 12221 | 0.160 |
Why?
|
Algorithms | 10 | 2010 | 3890 | 0.160 |
Why?
|
Abdominal Wall | 1 | 2020 | 184 | 0.150 |
Why?
|
Histocytochemistry | 2 | 2010 | 185 | 0.150 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 3 | 2011 | 476 | 0.150 |
Why?
|
Sarcoma | 3 | 2015 | 1725 | 0.150 |
Why?
|
Cell Differentiation | 5 | 2015 | 4078 | 0.140 |
Why?
|
Neurocytoma | 1 | 2016 | 17 | 0.140 |
Why?
|
Eflornithine | 3 | 2005 | 59 | 0.140 |
Why?
|
Receptors, Progesterone | 4 | 2012 | 1392 | 0.140 |
Why?
|
Leiomyoma | 3 | 2020 | 145 | 0.140 |
Why?
|
Rhabdomyosarcoma | 2 | 2000 | 341 | 0.140 |
Why?
|
Repressor Proteins | 2 | 2023 | 1664 | 0.140 |
Why?
|
Observer Variation | 3 | 2007 | 671 | 0.140 |
Why?
|
Histones | 3 | 2013 | 1466 | 0.140 |
Why?
|
Urogenital Neoplasms | 1 | 2017 | 108 | 0.140 |
Why?
|
Anticarcinogenic Agents | 4 | 2005 | 362 | 0.140 |
Why?
|
Maintenance Chemotherapy | 1 | 2017 | 202 | 0.140 |
Why?
|
Vulvar Lichen Sclerosus | 1 | 2015 | 7 | 0.140 |
Why?
|
Nuclear Proteins | 2 | 2023 | 3343 | 0.140 |
Why?
|
Reproducibility of Results | 10 | 2012 | 6009 | 0.140 |
Why?
|
Paired Box Transcription Factors | 1 | 2016 | 134 | 0.140 |
Why?
|
Risk | 1 | 2020 | 1972 | 0.130 |
Why?
|
Receptors, Estrogen | 5 | 2012 | 2086 | 0.130 |
Why?
|
Epithelial Cells | 4 | 2010 | 1818 | 0.130 |
Why?
|
Carcinoma, Papillary | 2 | 2010 | 584 | 0.130 |
Why?
|
Breast Neoplasms | 8 | 2015 | 15694 | 0.130 |
Why?
|
Keratin-6 | 2 | 2012 | 39 | 0.130 |
Why?
|
Keratin-5 | 2 | 2012 | 57 | 0.130 |
Why?
|
Alleles | 1 | 2021 | 2437 | 0.130 |
Why?
|
Mesothelioma, Cystic | 2 | 2005 | 3 | 0.130 |
Why?
|
Terminology as Topic | 2 | 2010 | 414 | 0.130 |
Why?
|
Watchful Waiting | 1 | 2017 | 289 | 0.130 |
Why?
|
Cell Shape | 2 | 2013 | 128 | 0.120 |
Why?
|
DNA Mismatch Repair | 1 | 2016 | 268 | 0.120 |
Why?
|
Glioma | 2 | 2016 | 1963 | 0.120 |
Why?
|
Texas | 7 | 2019 | 6311 | 0.120 |
Why?
|
In Situ Hybridization | 3 | 2011 | 1037 | 0.120 |
Why?
|
Trophoblastic Neoplasms | 2 | 2009 | 19 | 0.120 |
Why?
|
B7-H1 Antigen | 1 | 2021 | 1022 | 0.120 |
Why?
|
Mammary Glands, Human | 1 | 2015 | 184 | 0.120 |
Why?
|
Dysgerminoma | 1 | 2014 | 42 | 0.120 |
Why?
|
Risk Factors | 14 | 2020 | 17523 | 0.120 |
Why?
|
High-Throughput Nucleotide Sequencing | 2 | 2021 | 2291 | 0.120 |
Why?
|
Proto-Oncogene Proteins c-kit | 3 | 2005 | 479 | 0.120 |
Why?
|
Sensitivity and Specificity | 12 | 2011 | 4971 | 0.120 |
Why?
|
DNA, Neoplasm | 6 | 2013 | 1910 | 0.120 |
Why?
|
MART-1 Antigen | 2 | 2004 | 105 | 0.120 |
Why?
|
Chromosomes, Human, Pair 9 | 2 | 2005 | 290 | 0.120 |
Why?
|
Microphthalmia-Associated Transcription Factor | 2 | 2004 | 42 | 0.120 |
Why?
|
Neoplasms, Second Primary | 4 | 2006 | 1350 | 0.120 |
Why?
|
Monophenol Monooxygenase | 2 | 2004 | 59 | 0.120 |
Why?
|
Scattering, Radiation | 5 | 2005 | 316 | 0.120 |
Why?
|
DNA-Binding Proteins | 6 | 2008 | 4821 | 0.120 |
Why?
|
Cell Nucleus Size | 1 | 2013 | 3 | 0.120 |
Why?
|
Leukemia, Plasma Cell | 1 | 1993 | 42 | 0.120 |
Why?
|
Spectrum Analysis | 2 | 2011 | 139 | 0.110 |
Why?
|
Chemoradiotherapy, Adjuvant | 1 | 2016 | 565 | 0.110 |
Why?
|
S100 Proteins | 2 | 2004 | 181 | 0.110 |
Why?
|
Neoplasm Metastasis | 4 | 2015 | 5112 | 0.110 |
Why?
|
Cystadenoma | 2 | 2010 | 26 | 0.110 |
Why?
|
Antibodies | 1 | 2016 | 838 | 0.110 |
Why?
|
Neovascularization, Pathologic | 2 | 2015 | 1547 | 0.110 |
Why?
|
Prostatic Hyperplasia | 1 | 1994 | 210 | 0.110 |
Why?
|
Genes, ras | 1 | 2016 | 667 | 0.110 |
Why?
|
Liver Neoplasms | 2 | 2007 | 4557 | 0.110 |
Why?
|
Cell Size | 1 | 2013 | 136 | 0.110 |
Why?
|
Antigens, Neoplasm | 3 | 2004 | 1506 | 0.110 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 1 | 2015 | 328 | 0.110 |
Why?
|
Desmin | 4 | 2012 | 63 | 0.110 |
Why?
|
Condoms | 1 | 2012 | 53 | 0.110 |
Why?
|
Hemangioma | 1 | 2014 | 154 | 0.110 |
Why?
|
Urinary Bladder Neoplasms | 2 | 2002 | 2341 | 0.110 |
Why?
|
Antineoplastic Agents, Hormonal | 3 | 2012 | 840 | 0.100 |
Why?
|
Age Factors | 6 | 2016 | 5377 | 0.100 |
Why?
|
Image Enhancement | 3 | 2008 | 561 | 0.100 |
Why?
|
Menopause | 1 | 2012 | 159 | 0.100 |
Why?
|
Image Processing, Computer-Assisted | 10 | 2013 | 1648 | 0.100 |
Why?
|
Kidney Neoplasms | 2 | 2023 | 3022 | 0.100 |
Why?
|
Retinoblastoma-Like Protein p130 | 1 | 2010 | 18 | 0.100 |
Why?
|
Phytohemagglutinins | 1 | 2010 | 71 | 0.100 |
Why?
|
Sentinel Lymph Node Biopsy | 3 | 2009 | 1415 | 0.100 |
Why?
|
Acetylglucosamine | 1 | 2010 | 25 | 0.100 |
Why?
|
N-Acetylglucosaminyltransferases | 1 | 2010 | 46 | 0.100 |
Why?
|
Urethral Neoplasms | 2 | 2004 | 60 | 0.100 |
Why?
|
WT1 Proteins | 3 | 2005 | 106 | 0.090 |
Why?
|
Lectins | 1 | 2010 | 151 | 0.090 |
Why?
|
Collagen | 3 | 2003 | 752 | 0.090 |
Why?
|
Radiotherapy, Adjuvant | 3 | 2013 | 2231 | 0.090 |
Why?
|
Aorta, Abdominal | 1 | 2011 | 152 | 0.090 |
Why?
|
Tamoxifen | 3 | 2017 | 876 | 0.090 |
Why?
|
Prostheses and Implants | 1 | 2012 | 295 | 0.090 |
Why?
|
Platinum Compounds | 3 | 2017 | 131 | 0.090 |
Why?
|
Kaplan-Meier Estimate | 6 | 2016 | 6207 | 0.090 |
Why?
|
PAX2 Transcription Factor | 1 | 2009 | 43 | 0.090 |
Why?
|
Remission Induction | 3 | 2016 | 3569 | 0.090 |
Why?
|
ras Proteins | 1 | 2013 | 770 | 0.090 |
Why?
|
DNA, Viral | 3 | 2010 | 694 | 0.090 |
Why?
|
Actins | 4 | 2012 | 608 | 0.090 |
Why?
|
Pelvis | 1 | 2011 | 362 | 0.090 |
Why?
|
Child, Preschool | 4 | 2021 | 16273 | 0.080 |
Why?
|
Fallopian Tube Diseases | 1 | 2008 | 18 | 0.080 |
Why?
|
Ifosfamide | 1 | 2009 | 344 | 0.080 |
Why?
|
Teratocarcinoma | 1 | 2008 | 24 | 0.080 |
Why?
|
Proto-Oncogene Proteins | 2 | 2013 | 2488 | 0.080 |
Why?
|
Oral Surgical Procedures | 1 | 2008 | 32 | 0.080 |
Why?
|
Insulin-Like Growth Factor I | 1 | 2011 | 630 | 0.080 |
Why?
|
Colonic Diseases | 1 | 2008 | 71 | 0.080 |
Why?
|
Stromal Cells | 1 | 2012 | 825 | 0.080 |
Why?
|
Trophoblasts | 1 | 2009 | 138 | 0.080 |
Why?
|
Staining and Labeling | 3 | 2004 | 429 | 0.080 |
Why?
|
Transcription Factors | 4 | 2008 | 5270 | 0.080 |
Why?
|
Artifacts | 2 | 2009 | 532 | 0.080 |
Why?
|
Molecular Targeted Therapy | 2 | 2016 | 2330 | 0.080 |
Why?
|
Calmodulin-Binding Proteins | 1 | 2008 | 86 | 0.080 |
Why?
|
Blood Vessels | 1 | 2009 | 217 | 0.080 |
Why?
|
RNA-Binding Protein EWS | 1 | 2008 | 98 | 0.080 |
Why?
|
Tissue Embedding | 2 | 2004 | 28 | 0.080 |
Why?
|
Lung Neoplasms | 3 | 2020 | 11538 | 0.080 |
Why?
|
Tumor Burden | 1 | 2013 | 1987 | 0.080 |
Why?
|
Anatomy, Cross-Sectional | 1 | 2007 | 24 | 0.080 |
Why?
|
Pattern Recognition, Automated | 1 | 2008 | 125 | 0.070 |
Why?
|
Child | 5 | 2021 | 29154 | 0.070 |
Why?
|
Microsatellite Repeats | 2 | 2006 | 575 | 0.070 |
Why?
|
Lasers | 3 | 1996 | 198 | 0.070 |
Why?
|
Male | 12 | 2022 | 123000 | 0.070 |
Why?
|
Signal Processing, Computer-Assisted | 1 | 2008 | 209 | 0.070 |
Why?
|
Models, Biological | 3 | 2005 | 3254 | 0.070 |
Why?
|
Artificial Intelligence | 3 | 2008 | 388 | 0.070 |
Why?
|
Equipment Design | 2 | 2011 | 1204 | 0.070 |
Why?
|
Polyps | 2 | 2005 | 74 | 0.070 |
Why?
|
DNA Sequence, Unstable | 1 | 2006 | 7 | 0.070 |
Why?
|
Intestinal Obstruction | 1 | 2008 | 202 | 0.070 |
Why?
|
Neoplasms, Squamous Cell | 1 | 2006 | 87 | 0.070 |
Why?
|
Pilot Projects | 4 | 2009 | 2803 | 0.070 |
Why?
|
Leuprolide | 2 | 2017 | 65 | 0.070 |
Why?
|
Pelvic Neoplasms | 1 | 2007 | 189 | 0.070 |
Why?
|
Fluorescence | 2 | 2003 | 195 | 0.070 |
Why?
|
Logistic Models | 4 | 2013 | 3441 | 0.070 |
Why?
|
Membrane Glycoproteins | 1 | 2010 | 1073 | 0.070 |
Why?
|
Histological Techniques | 1 | 2005 | 65 | 0.070 |
Why?
|
Cell Proliferation | 3 | 2013 | 7226 | 0.070 |
Why?
|
Abdominal Neoplasms | 1 | 2007 | 231 | 0.070 |
Why?
|
Robotics | 1 | 2009 | 359 | 0.070 |
Why?
|
Age of Onset | 1 | 2007 | 827 | 0.070 |
Why?
|
Proportional Hazards Models | 4 | 2016 | 4988 | 0.070 |
Why?
|
Reoperation | 1 | 2010 | 1382 | 0.070 |
Why?
|
Paranasal Sinus Neoplasms | 1 | 2008 | 285 | 0.070 |
Why?
|
NAD | 2 | 2003 | 89 | 0.060 |
Why?
|
Chromatin | 3 | 2005 | 942 | 0.060 |
Why?
|
Diagnostic Imaging | 1 | 2012 | 1162 | 0.060 |
Why?
|
Mucin-1 | 1 | 2004 | 127 | 0.060 |
Why?
|
Cadherins | 1 | 2007 | 660 | 0.060 |
Why?
|
Microscopy, Fluorescence | 3 | 2001 | 769 | 0.060 |
Why?
|
Superantigens | 1 | 2004 | 29 | 0.060 |
Why?
|
Aneuploidy | 1 | 2005 | 369 | 0.060 |
Why?
|
Cyclin E | 1 | 2006 | 267 | 0.060 |
Why?
|
Gene Rearrangement | 1 | 2008 | 783 | 0.060 |
Why?
|
Optics and Photonics | 1 | 2005 | 146 | 0.060 |
Why?
|
Receptor, ErbB-2 | 3 | 2013 | 2518 | 0.060 |
Why?
|
Gold Colloid | 1 | 2003 | 3 | 0.060 |
Why?
|
Pathology | 1 | 2004 | 101 | 0.060 |
Why?
|
Clomiphene | 1 | 2003 | 12 | 0.060 |
Why?
|
Proto-Oncogene Proteins c-abl | 1 | 2003 | 79 | 0.060 |
Why?
|
Megestrol Acetate | 1 | 2003 | 29 | 0.060 |
Why?
|
Estrone | 1 | 2003 | 31 | 0.060 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 3 | 2010 | 3639 | 0.060 |
Why?
|
Norway | 2 | 2013 | 30 | 0.060 |
Why?
|
Neoplasms, Glandular and Epithelial | 1 | 2008 | 519 | 0.060 |
Why?
|
Langerhans Cells | 1 | 2003 | 50 | 0.060 |
Why?
|
SOXF Transcription Factors | 1 | 2023 | 34 | 0.060 |
Why?
|
Guinea Pigs | 1 | 2003 | 241 | 0.060 |
Why?
|
Dihydrotestosterone | 1 | 2003 | 118 | 0.060 |
Why?
|
Receptor, Platelet-Derived Growth Factor beta | 1 | 2003 | 153 | 0.060 |
Why?
|
Genital Diseases, Female | 1 | 2003 | 60 | 0.050 |
Why?
|
Chorionic Gonadotropin | 1 | 2003 | 130 | 0.050 |
Why?
|
Carrier Proteins | 1 | 2011 | 2022 | 0.050 |
Why?
|
Animals | 6 | 2020 | 59536 | 0.050 |
Why?
|
Prolactin | 1 | 2003 | 155 | 0.050 |
Why?
|
Prostatic Neoplasms | 2 | 2004 | 5767 | 0.050 |
Why?
|
Th1 Cells | 1 | 2004 | 250 | 0.050 |
Why?
|
Tissue Array Analysis | 3 | 2011 | 760 | 0.050 |
Why?
|
Genotype | 3 | 2020 | 4109 | 0.050 |
Why?
|
Growth Hormone | 1 | 2003 | 226 | 0.050 |
Why?
|
ErbB Receptors | 2 | 2003 | 2295 | 0.050 |
Why?
|
Doxorubicin | 1 | 2009 | 3005 | 0.050 |
Why?
|
Adenofibroma | 1 | 2002 | 20 | 0.050 |
Why?
|
DNA Mutational Analysis | 3 | 2016 | 2283 | 0.050 |
Why?
|
RNA-Binding Proteins | 1 | 2008 | 984 | 0.050 |
Why?
|
Gene Expression Regulation, Neoplastic | 5 | 2011 | 8873 | 0.050 |
Why?
|
Imaging, Three-Dimensional | 1 | 2007 | 925 | 0.050 |
Why?
|
Gene Expression Profiling | 5 | 2011 | 5159 | 0.050 |
Why?
|
Necrosis | 2 | 2013 | 580 | 0.050 |
Why?
|
Thyroid Diseases | 1 | 2002 | 85 | 0.050 |
Why?
|
Merkel cell polyomavirus | 1 | 2021 | 30 | 0.050 |
Why?
|
Receptors, Growth Factor | 2 | 2002 | 157 | 0.050 |
Why?
|
ROC Curve | 3 | 2011 | 1183 | 0.050 |
Why?
|
Trachelectomy | 1 | 2021 | 28 | 0.050 |
Why?
|
Ribonuclease III | 1 | 2022 | 182 | 0.050 |
Why?
|
World Health Organization | 2 | 2013 | 316 | 0.050 |
Why?
|
Cell Count | 2 | 2012 | 508 | 0.050 |
Why?
|
Testosterone | 2 | 2003 | 619 | 0.050 |
Why?
|
Carcinoma, Transitional Cell | 1 | 2008 | 962 | 0.050 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2004 | 703 | 0.050 |
Why?
|
Proteomics | 2 | 2022 | 1380 | 0.050 |
Why?
|
Mass Screening | 8 | 2011 | 1509 | 0.050 |
Why?
|
Cytoskeletal Proteins | 1 | 2003 | 492 | 0.050 |
Why?
|
Epigenomics | 1 | 2022 | 266 | 0.050 |
Why?
|
Pelvic Exenteration | 1 | 2021 | 108 | 0.050 |
Why?
|
Acetic Acid | 1 | 2000 | 34 | 0.050 |
Why?
|
Antibodies, Monoclonal | 5 | 2009 | 4367 | 0.050 |
Why?
|
Head and Neck Neoplasms | 1 | 1996 | 3976 | 0.050 |
Why?
|
Hyperandrogenism | 1 | 2000 | 22 | 0.050 |
Why?
|
DEAD-box RNA Helicases | 1 | 2022 | 255 | 0.050 |
Why?
|
Neuroectodermal Tumors | 1 | 2000 | 35 | 0.050 |
Why?
|
Baltimore | 1 | 2019 | 28 | 0.050 |
Why?
|
Camptothecin | 1 | 2003 | 517 | 0.050 |
Why?
|
Aromatase Inhibitors | 1 | 2022 | 305 | 0.050 |
Why?
|
Dendritic Cells | 1 | 2006 | 1085 | 0.050 |
Why?
|
Histiocytosis, Langerhans-Cell | 1 | 2003 | 261 | 0.050 |
Why?
|
RNA, Messenger | 3 | 2022 | 6150 | 0.050 |
Why?
|
Rosaniline Dyes | 2 | 2004 | 108 | 0.040 |
Why?
|
Blotting, Western | 3 | 2011 | 3536 | 0.040 |
Why?
|
Glioblastoma | 1 | 2010 | 1797 | 0.040 |
Why?
|
Immunoconjugates | 1 | 2003 | 279 | 0.040 |
Why?
|
Postoperative Care | 1 | 2003 | 739 | 0.040 |
Why?
|
Peptide Fragments | 1 | 2005 | 1271 | 0.040 |
Why?
|
Estradiol | 1 | 2003 | 748 | 0.040 |
Why?
|
Carcinoma, Merkel Cell | 1 | 2021 | 155 | 0.040 |
Why?
|
Genomics | 2 | 2022 | 2738 | 0.040 |
Why?
|
Monitoring, Intraoperative | 1 | 2021 | 264 | 0.040 |
Why?
|
Intestinal Neoplasms | 1 | 2001 | 189 | 0.040 |
Why?
|
Vaginal Smears | 3 | 2005 | 192 | 0.040 |
Why?
|
Uterine Cervicitis | 4 | 2003 | 7 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2005 | 1493 | 0.040 |
Why?
|
Ploidies | 1 | 2019 | 248 | 0.040 |
Why?
|
Lymphoma, B-Cell, Marginal Zone | 1 | 2001 | 301 | 0.040 |
Why?
|
Inhibitor of Apoptosis Proteins | 2 | 2011 | 202 | 0.040 |
Why?
|
Bevacizumab | 1 | 2021 | 938 | 0.040 |
Why?
|
Laser Therapy | 1 | 2002 | 411 | 0.040 |
Why?
|
Incidence | 3 | 2016 | 5673 | 0.040 |
Why?
|
Cell Adhesion Molecules | 1 | 2000 | 577 | 0.040 |
Why?
|
Reference Values | 3 | 2004 | 1099 | 0.040 |
Why?
|
Medroxyprogesterone Acetate | 1 | 2017 | 55 | 0.040 |
Why?
|
Chromosome Aberrations | 1 | 2004 | 1960 | 0.040 |
Why?
|
Hepatocyte Growth Factor | 1 | 1997 | 142 | 0.040 |
Why?
|
Survivors | 1 | 2022 | 1031 | 0.040 |
Why?
|
Paraffin Embedding | 2 | 2010 | 226 | 0.040 |
Why?
|
Hydatidiform Mole | 1 | 1996 | 38 | 0.040 |
Why?
|
Etoposide | 2 | 1996 | 870 | 0.040 |
Why?
|
Mouth Neoplasms | 1 | 2002 | 713 | 0.040 |
Why?
|
Trans-Activators | 1 | 2003 | 1555 | 0.040 |
Why?
|
Polymerase Chain Reaction | 3 | 2010 | 3203 | 0.040 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2020 | 2594 | 0.030 |
Why?
|
Sarcoma, Ewing | 1 | 2000 | 406 | 0.030 |
Why?
|
Leiomyomatosis | 1 | 1995 | 12 | 0.030 |
Why?
|
Tumor Cells, Cultured | 3 | 2013 | 5395 | 0.030 |
Why?
|
Prostate-Specific Antigen | 2 | 2004 | 993 | 0.030 |
Why?
|
Pancreatic Neoplasms | 1 | 1993 | 5061 | 0.030 |
Why?
|
MAP Kinase Signaling System | 1 | 2020 | 848 | 0.030 |
Why?
|
Cytoplasm | 3 | 2003 | 652 | 0.030 |
Why?
|
PTEN Phosphohydrolase | 1 | 2020 | 986 | 0.030 |
Why?
|
Evidence-Based Medicine | 1 | 2021 | 1085 | 0.030 |
Why?
|
Multivariate Analysis | 4 | 2013 | 4298 | 0.030 |
Why?
|
Antigens, CD | 1 | 2000 | 1385 | 0.030 |
Why?
|
Nocardia Infections | 1 | 1995 | 34 | 0.030 |
Why?
|
Up-Regulation | 2 | 2011 | 2450 | 0.030 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2021 | 1533 | 0.030 |
Why?
|
Pregnancy | 4 | 2002 | 7573 | 0.030 |
Why?
|
Epigenesis, Genetic | 1 | 2022 | 1399 | 0.030 |
Why?
|
Epidermolysis Bullosa | 1 | 1994 | 15 | 0.030 |
Why?
|
Cytokines | 1 | 2004 | 2809 | 0.030 |
Why?
|
Acid Phosphatase | 1 | 1994 | 59 | 0.030 |
Why?
|
Factor Analysis, Statistical | 1 | 2015 | 356 | 0.030 |
Why?
|
Papanicolaou Test | 2 | 2005 | 141 | 0.030 |
Why?
|
Keratin-7 | 2 | 2004 | 52 | 0.030 |
Why?
|
Placebos | 2 | 2005 | 437 | 0.030 |
Why?
|
Urethral Diseases | 1 | 1994 | 36 | 0.030 |
Why?
|
Internet | 1 | 2019 | 706 | 0.030 |
Why?
|
Uterus | 1 | 2019 | 678 | 0.030 |
Why?
|
Microtomy | 2 | 2004 | 17 | 0.030 |
Why?
|
Eosine Yellowish-(YS) | 1 | 2013 | 33 | 0.030 |
Why?
|
Hematoxylin | 1 | 2013 | 34 | 0.030 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2000 | 1039 | 0.030 |
Why?
|
Soft Tissue Infections | 1 | 1995 | 102 | 0.030 |
Why?
|
Republic of Korea | 1 | 2013 | 70 | 0.030 |
Why?
|
Ontario | 1 | 2013 | 98 | 0.030 |
Why?
|
Thyroglossal Cyst | 1 | 1993 | 14 | 0.030 |
Why?
|
Facial Paralysis | 1 | 1993 | 60 | 0.030 |
Why?
|
Genes, BRCA2 | 1 | 2015 | 309 | 0.030 |
Why?
|
Mexico | 1 | 2013 | 259 | 0.030 |
Why?
|
Deafness | 1 | 1993 | 82 | 0.030 |
Why?
|
Paclitaxel | 2 | 2015 | 1996 | 0.030 |
Why?
|
Larynx | 1 | 1994 | 134 | 0.030 |
Why?
|
Hamartoma | 1 | 1994 | 115 | 0.030 |
Why?
|
Aspergillus fumigatus | 1 | 1993 | 135 | 0.030 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 2000 | 1216 | 0.030 |
Why?
|
Genes, BRCA1 | 1 | 2015 | 387 | 0.030 |
Why?
|
MAP Kinase Kinase Kinases | 1 | 2013 | 190 | 0.030 |
Why?
|
AIDS-Related Opportunistic Infections | 1 | 1993 | 163 | 0.030 |
Why?
|
Peritoneal Lavage | 1 | 2012 | 21 | 0.030 |
Why?
|
Mice, Nude | 2 | 2010 | 4307 | 0.030 |
Why?
|
Temporal Bone | 1 | 1993 | 102 | 0.030 |
Why?
|
HIV Core Protein p24 | 1 | 1992 | 20 | 0.030 |
Why?
|
Triazoles | 1 | 2017 | 617 | 0.030 |
Why?
|
Nitriles | 1 | 2017 | 906 | 0.030 |
Why?
|
Cisplatin | 3 | 2006 | 2432 | 0.030 |
Why?
|
Microscopy, Interference | 1 | 2011 | 16 | 0.030 |
Why?
|
Classification | 1 | 2011 | 41 | 0.030 |
Why?
|
Vagina | 1 | 2014 | 317 | 0.030 |
Why?
|
Maternal-Fetal Exchange | 1 | 1992 | 90 | 0.030 |
Why?
|
Receptors, Steroid | 1 | 2013 | 286 | 0.030 |
Why?
|
Dilatation and Curettage | 1 | 2011 | 8 | 0.030 |
Why?
|
Aspergillosis | 1 | 1993 | 246 | 0.030 |
Why?
|
China | 1 | 2013 | 606 | 0.030 |
Why?
|
Cell Death | 1 | 2013 | 671 | 0.020 |
Why?
|
Mixed Tumor, Mullerian | 1 | 2011 | 37 | 0.020 |
Why?
|
Cell Survival | 2 | 2011 | 3045 | 0.020 |
Why?
|
Cholestasis | 1 | 1993 | 203 | 0.020 |
Why?
|
Genotyping Techniques | 1 | 2011 | 166 | 0.020 |
Why?
|
Pancreatitis | 1 | 1993 | 267 | 0.020 |
Why?
|
Cell Growth Processes | 1 | 2011 | 342 | 0.020 |
Why?
|
Cell Dedifferentiation | 1 | 2011 | 96 | 0.020 |
Why?
|
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2011 | 208 | 0.020 |
Why?
|
Feasibility Studies | 2 | 2009 | 2292 | 0.020 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2016 | 2232 | 0.020 |
Why?
|
Glycosylation | 1 | 2010 | 213 | 0.020 |
Why?
|
Benzimidazoles | 1 | 2013 | 428 | 0.020 |
Why?
|
beta Catenin | 2 | 2006 | 688 | 0.020 |
Why?
|
Heterocyclic Compounds, 3-Ring | 1 | 2011 | 146 | 0.020 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2001 | 1664 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2011 | 1586 | 0.020 |
Why?
|
Endothelium | 1 | 2010 | 158 | 0.020 |
Why?
|
Gene Expression | 2 | 2009 | 3570 | 0.020 |
Why?
|
Antibodies, Monoclonal, Humanized | 1 | 2021 | 3251 | 0.020 |
Why?
|
Injections, Intraperitoneal | 1 | 2010 | 197 | 0.020 |
Why?
|
Groin | 2 | 2003 | 74 | 0.020 |
Why?
|
Mice, Inbred C57BL | 1 | 2020 | 6942 | 0.020 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2011 | 528 | 0.020 |
Why?
|
Retinoblastoma Protein | 1 | 2011 | 335 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2011 | 756 | 0.020 |
Why?
|
Biomarkers | 3 | 2012 | 5047 | 0.020 |
Why?
|
Receptor, IGF Type 1 | 1 | 2011 | 347 | 0.020 |
Why?
|
Choriocarcinoma | 1 | 2009 | 47 | 0.020 |
Why?
|
Mice | 3 | 2020 | 34495 | 0.020 |
Why?
|
Regression Analysis | 1 | 2012 | 1546 | 0.020 |
Why?
|
Carcinoma, Adenosquamous | 1 | 2009 | 103 | 0.020 |
Why?
|
Alphapapillomavirus | 1 | 2010 | 171 | 0.020 |
Why?
|
Computer Simulation | 2 | 2005 | 1529 | 0.020 |
Why?
|
Cyclooxygenase 2 | 1 | 2011 | 483 | 0.020 |
Why?
|
Signal Transduction | 2 | 2020 | 11965 | 0.020 |
Why?
|
Transplantation, Heterologous | 1 | 2010 | 1082 | 0.020 |
Why?
|
Pyrazines | 1 | 2011 | 495 | 0.020 |
Why?
|
Gene Knockdown Techniques | 1 | 2011 | 1077 | 0.020 |
Why?
|
Northern Ireland | 1 | 2007 | 4 | 0.020 |
Why?
|
Adenoma | 1 | 1993 | 716 | 0.020 |
Why?
|
Thyroid Nuclear Factor 1 | 1 | 2007 | 52 | 0.020 |
Why?
|
Placenta | 1 | 1992 | 516 | 0.020 |
Why?
|
Otorhinolaryngologic Surgical Procedures | 1 | 2008 | 60 | 0.020 |
Why?
|
Gene Transfer Techniques | 1 | 2010 | 716 | 0.020 |
Why?
|
Immunophenotyping | 1 | 2012 | 1681 | 0.020 |
Why?
|
Registries | 1 | 2015 | 2170 | 0.020 |
Why?
|
RNA, Viral | 1 | 2010 | 671 | 0.020 |
Why?
|
Mitosis | 1 | 2009 | 615 | 0.020 |
Why?
|
Drug Administration Schedule | 2 | 2007 | 3472 | 0.020 |
Why?
|
Papillomavirus E7 Proteins | 1 | 2006 | 64 | 0.020 |
Why?
|
Surveys and Questionnaires | 1 | 2019 | 5687 | 0.020 |
Why?
|
Radiotherapy | 2 | 2006 | 1824 | 0.020 |
Why?
|
Medical Records | 1 | 2007 | 415 | 0.020 |
Why?
|
Discriminant Analysis | 2 | 1996 | 48 | 0.020 |
Why?
|
Colposcopes | 1 | 2005 | 2 | 0.020 |
Why?
|
Matrix Metalloproteinase 9 | 1 | 2007 | 360 | 0.020 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2009 | 665 | 0.020 |
Why?
|
Oncogene Proteins, Viral | 1 | 2006 | 133 | 0.020 |
Why?
|
Sampling Studies | 1 | 2006 | 170 | 0.020 |
Why?
|
Tissue Culture Techniques | 1 | 2006 | 114 | 0.020 |
Why?
|
Cell Line, Tumor | 2 | 2011 | 14551 | 0.020 |
Why?
|
Diverticulum | 1 | 2005 | 35 | 0.020 |
Why?
|
Suction | 1 | 2005 | 104 | 0.020 |
Why?
|
Antigen Presentation | 1 | 2006 | 272 | 0.020 |
Why?
|
Human papillomavirus 16 | 1 | 2007 | 256 | 0.020 |
Why?
|
Imidazoles | 1 | 2011 | 999 | 0.020 |
Why?
|
Sialoglycoproteins | 1 | 2005 | 151 | 0.020 |
Why?
|
MutS Homolog 3 Protein | 1 | 2004 | 12 | 0.020 |
Why?
|
Cyclophosphamide | 2 | 2006 | 3001 | 0.020 |
Why?
|
Carcinoma, Renal Cell | 1 | 1997 | 2326 | 0.020 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2010 | 992 | 0.020 |
Why?
|
Lewis X Antigen | 1 | 2004 | 46 | 0.020 |
Why?
|
Osteopontin | 1 | 2005 | 148 | 0.020 |
Why?
|
Prospective Studies | 3 | 2013 | 12873 | 0.020 |
Why?
|
Phosphorylation | 1 | 2013 | 4804 | 0.020 |
Why?
|
Molecular Biology | 1 | 2006 | 176 | 0.020 |
Why?
|
Colonoscopy | 1 | 2008 | 518 | 0.020 |
Why?
|
Immunity, Cellular | 1 | 2006 | 419 | 0.020 |
Why?
|
DNA | 2 | 2003 | 2693 | 0.020 |
Why?
|
Corpus Luteum | 1 | 2004 | 32 | 0.020 |
Why?
|
Quality Control | 1 | 2005 | 457 | 0.020 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2010 | 2508 | 0.020 |
Why?
|
Frameshift Mutation | 1 | 2004 | 220 | 0.010 |
Why?
|
Vacuum | 1 | 2003 | 42 | 0.010 |
Why?
|
Tissue Fixation | 1 | 2004 | 136 | 0.010 |
Why?
|
Probability | 2 | 1996 | 866 | 0.010 |
Why?
|
Enterotoxins | 1 | 2004 | 112 | 0.010 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2011 | 2054 | 0.010 |
Why?
|
Spectrometry, X-Ray Emission | 1 | 2003 | 6 | 0.010 |
Why?
|
Flavin-Adenine Dinucleotide | 1 | 2003 | 13 | 0.010 |
Why?
|
Protein Isoforms | 1 | 2006 | 842 | 0.010 |
Why?
|
Finite Element Analysis | 1 | 2003 | 57 | 0.010 |
Why?
|
Spectrophotometry, Ultraviolet | 1 | 2003 | 71 | 0.010 |
Why?
|
alpha-Fetoproteins | 1 | 2004 | 237 | 0.010 |
Why?
|
Bandages | 1 | 2003 | 71 | 0.010 |
Why?
|
Perineum | 1 | 2003 | 107 | 0.010 |
Why?
|
Infant | 2 | 1996 | 13310 | 0.010 |
Why?
|
Optical Fibers | 1 | 2003 | 37 | 0.010 |
Why?
|
Particle Size | 1 | 2003 | 182 | 0.010 |
Why?
|
Infusions, Parenteral | 1 | 2003 | 191 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 2 | 2002 | 7551 | 0.010 |
Why?
|
Th2 Cells | 1 | 2004 | 257 | 0.010 |
Why?
|
Microscopy, Electron | 1 | 2003 | 600 | 0.010 |
Why?
|
Skin Transplantation | 1 | 2003 | 173 | 0.010 |
Why?
|
Muscle, Smooth | 1 | 2003 | 236 | 0.010 |
Why?
|
Vascular Endothelial Growth Factor Receptor-3 | 1 | 2002 | 15 | 0.010 |
Why?
|
Microtubule-Associated Proteins | 1 | 2005 | 534 | 0.010 |
Why?
|
Luminescent Proteins | 1 | 2003 | 289 | 0.010 |
Why?
|
Mastectomy | 1 | 2009 | 1534 | 0.010 |
Why?
|
Thyroid Neoplasms | 1 | 1993 | 1866 | 0.010 |
Why?
|
Cheilitis | 1 | 2001 | 4 | 0.010 |
Why?
|
Fiber Optic Technology | 1 | 2003 | 142 | 0.010 |
Why?
|
Cystadenocarcinoma | 1 | 2001 | 21 | 0.010 |
Why?
|
Photosensitivity Disorders | 1 | 2001 | 23 | 0.010 |
Why?
|
Light | 1 | 2003 | 245 | 0.010 |
Why?
|
Genome, Human | 1 | 2010 | 1869 | 0.010 |
Why?
|
Photobiology | 1 | 2001 | 2 | 0.010 |
Why?
|
Antigens, Bacterial | 1 | 2004 | 354 | 0.010 |
Why?
|
Biopsy, Needle | 1 | 2006 | 1363 | 0.010 |
Why?
|
Ovarian Cysts | 1 | 2001 | 43 | 0.010 |
Why?
|
Medical Futility | 1 | 2001 | 54 | 0.010 |
Why?
|
Interleukin-10 | 1 | 2004 | 478 | 0.010 |
Why?
|
Omentum | 1 | 2002 | 96 | 0.010 |
Why?
|
Fertility | 1 | 2004 | 336 | 0.010 |
Why?
|
Veins | 1 | 2002 | 157 | 0.010 |
Why?
|
17-alpha-Hydroxyprogesterone | 1 | 2000 | 6 | 0.010 |
Why?
|
Linear Models | 1 | 2004 | 1085 | 0.010 |
Why?
|
Databases, Factual | 1 | 2007 | 2218 | 0.010 |
Why?
|
12E7 Antigen | 1 | 2000 | 11 | 0.010 |
Why?
|
Interleukin-2 | 1 | 2004 | 842 | 0.010 |
Why?
|
Data Interpretation, Statistical | 1 | 2003 | 482 | 0.010 |
Why?
|
Mucins | 1 | 2001 | 285 | 0.010 |
Why?
|
Arteries | 1 | 2002 | 274 | 0.010 |
Why?
|
Myoglobin | 1 | 2000 | 116 | 0.010 |
Why?
|
Antigens, CD34 | 1 | 2002 | 593 | 0.010 |
Why?
|
Carcinoma, Signet Ring Cell | 1 | 2001 | 170 | 0.010 |
Why?
|
Cross-Over Studies | 1 | 2001 | 460 | 0.010 |
Why?
|
Pelvic Pain | 1 | 2000 | 48 | 0.010 |
Why?
|
Infusions, Intravenous | 1 | 2003 | 1382 | 0.010 |
Why?
|
Antigens, CD20 | 1 | 2000 | 206 | 0.010 |
Why?
|
Interferon-gamma | 1 | 2004 | 1144 | 0.010 |
Why?
|
Chromosomes, Human, Pair 22 | 1 | 2000 | 169 | 0.010 |
Why?
|
CD3 Complex | 1 | 2000 | 314 | 0.010 |
Why?
|
HIV Infections | 1 | 1992 | 2134 | 0.010 |
Why?
|
Adjuvants, Immunologic | 1 | 2003 | 657 | 0.010 |
Why?
|
Exanthema | 1 | 2001 | 211 | 0.010 |
Why?
|
Imatinib Mesylate | 1 | 2003 | 1665 | 0.010 |
Why?
|
Double-Blind Method | 1 | 2005 | 2588 | 0.010 |
Why?
|
Inflammation | 1 | 2009 | 2522 | 0.010 |
Why?
|
Sezary Syndrome | 1 | 2000 | 159 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2010 | 4549 | 0.010 |
Why?
|
Monte Carlo Method | 1 | 2001 | 671 | 0.010 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2004 | 1538 | 0.010 |
Why?
|
Spectrum Analysis, Raman | 1 | 1998 | 41 | 0.010 |
Why?
|
Chromosomes, Human, Pair 11 | 1 | 2000 | 402 | 0.010 |
Why?
|
Protein Kinase Inhibitors | 1 | 2013 | 4757 | 0.010 |
Why?
|
Base Sequence | 1 | 2004 | 4917 | 0.010 |
Why?
|
Benzamides | 1 | 2003 | 1832 | 0.010 |
Why?
|
Transfection | 1 | 2003 | 2944 | 0.010 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2002 | 661 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 2 | 2009 | 7702 | 0.010 |
Why?
|
Molecular Sequence Data | 1 | 2004 | 6089 | 0.010 |
Why?
|
Endothelium, Vascular | 1 | 2002 | 891 | 0.010 |
Why?
|
Patient Compliance | 1 | 2001 | 667 | 0.010 |
Why?
|
Recurrence | 1 | 2005 | 4758 | 0.010 |
Why?
|
Mycosis Fungoides | 1 | 2000 | 320 | 0.010 |
Why?
|
Metaplasia | 1 | 1998 | 383 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2007 | 4320 | 0.010 |
Why?
|
Dactinomycin | 1 | 1996 | 145 | 0.010 |
Why?
|
Surgical Procedures, Operative | 1 | 2000 | 383 | 0.010 |
Why?
|
Contrast Media | 1 | 2003 | 1472 | 0.010 |
Why?
|
United States | 1 | 2013 | 15433 | 0.010 |
Why?
|
Enzyme Inhibitors | 1 | 2003 | 1879 | 0.010 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2003 | 1756 | 0.010 |
Why?
|
Transcription, Genetic | 1 | 2004 | 3154 | 0.010 |
Why?
|
Software | 1 | 2003 | 1321 | 0.010 |
Why?
|
Nocardia asteroides | 1 | 1995 | 4 | 0.010 |
Why?
|
Intraoperative Period | 1 | 1995 | 246 | 0.010 |
Why?
|
Smoking | 1 | 2005 | 2440 | 0.010 |
Why?
|
Statistics, Nonparametric | 1 | 1997 | 980 | 0.010 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2009 | 5178 | 0.010 |
Why?
|
Injections, Intradermal | 1 | 1994 | 58 | 0.010 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 1997 | 604 | 0.010 |
Why?
|
Translocation, Genetic | 1 | 2000 | 1245 | 0.010 |
Why?
|
Piperazines | 1 | 2003 | 2101 | 0.010 |
Why?
|
Peptides | 1 | 2000 | 1479 | 0.010 |
Why?
|
Aging | 1 | 2002 | 1582 | 0.010 |
Why?
|
Hyoid Bone | 1 | 1993 | 8 | 0.010 |
Why?
|
Leg | 1 | 1995 | 226 | 0.010 |
Why?
|
T-Lymphocytes | 1 | 2006 | 3869 | 0.010 |
Why?
|
Lymphoma, B-Cell | 1 | 2000 | 895 | 0.010 |
Why?
|
Methotrexate | 1 | 1996 | 999 | 0.010 |
Why?
|
Cell Division | 1 | 1997 | 2489 | 0.010 |
Why?
|
Phenotype | 1 | 2004 | 6295 | 0.010 |
Why?
|
Cystectomy | 1 | 1997 | 623 | 0.010 |
Why?
|
Intraoperative Care | 1 | 1994 | 259 | 0.010 |
Why?
|
Forecasting | 1 | 1996 | 694 | 0.010 |
Why?
|
Life Style | 1 | 1996 | 612 | 0.010 |
Why?
|
Trachea | 1 | 1994 | 259 | 0.010 |
Why?
|
Vincristine | 1 | 1996 | 1511 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2000 | 5637 | 0.010 |
Why?
|
Tracheostomy | 1 | 1994 | 243 | 0.010 |
Why?
|
Administration, Oral | 1 | 1995 | 1544 | 0.010 |
Why?
|
Pyrimidines | 1 | 2003 | 3518 | 0.010 |
Why?
|
Preoperative Care | 1 | 1995 | 1529 | 0.010 |
Why?
|
Salvage Therapy | 1 | 1995 | 2054 | 0.000 |
Why?
|